View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Michael Piccolo
  • Michael Piccolo

Daily Recap: TASK, STAA, CCRN, HZO, AES, RNA, ARKO, FUBO, BARK, SITM, ...

TaskUs, Inc. (TASK - $11.11)AI Pivot Underway, We Think Up to the TASK; Mike Piccolo Initiating Coverage at OUTPERFORM with $15 Price Target. We are initiating coverage on TASK with an OUTPERFORM rating and a price target of $15 per share as we believe shares represent an attractive risk/reward opp

 PRESS RELEASE

Iridex Announces Plans to Relocate Headquarters

Iridex Announces Plans to Relocate Headquarters Move expected to generate significant cost savings MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced its intent to relocate the Company’s headquarters from Mountain View, California to San Jose, California. On January 26, 2026, the Company signed a non-binding letter of intent for a new lease (the “Lease”). The...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 13, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Iridex Announces Preliminary Operational and Financial Results for Fou...

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 Demonstrating continued revenue growth, operational efficiencies and positive cash flow MOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourt...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: January 8, 2026

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Iridex Announces the Publication of an Independent Study Demonstrating...

Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a recently published independent, retrospective study in Ophthalmology and Therapy. The study demonstrates that retreatment of tra...

 PRESS RELEASE

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical ...

Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments f...

 PRESS RELEASE

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

Iridex to Present at the Sidoti Year-End Virtual Investor Conference MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced plans to participate in the upcoming Sidoti Year-End Virtual Investor Conference. Management is scheduled to present on Thursday, December 11 at 10:45 am ET. Interested parties may access a live and archived webcast of the presentation on the “Even...

Glaukos Corp: 1 director

A director at Glaukos Corp sold 19,340 shares at 90.000USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Moody's Ratings assigns Baa3 rating to Baxter's senior notes; outlook ...

Moody's Ratings (Moody's) assigned a Baa3 rating to the proposed new senior unsecured notes issuance of Baxter International Inc. (Baxter). At the same time, we assigned a (P)Baa3 rating to Baxter's senior unsecured shelf registration. There are no changes to Baxter's existing ratings including the ...

Baxter International Inc.: Update following downgrade to Baa3

Our credit view of this issuer reflects its elevated financial leverage, with delays in reaching previously stated deleveraging targets.

Moody's Ratings downgrades Baxter to Baa3/P-3; outlook is stable

Moody's Ratings (Moody's) downgraded the ratings of Baxter International Inc. (Baxter) including the senior unsecured ratings to Baa3 from Baa2 and the commercial paper rating to Prime-3 from Prime-2. The outlook is stable. Previously, the ratings were on review for downgrade. This action concludes ...

 PRESS RELEASE

Iridex Reports Third Quarter 2025 Financial Results

Iridex Reports Third Quarter 2025 Financial Results MOUNTAIN VIEW, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended September 27, 2025. Third Quarter 2025 Financial Highlights Generated total revenue of $12.5 million, representing growth of 8% year-over-year compared to $11.6 million in the prior year quarterCyclo G6® product fa...

Moody's Ratings reviews Baxter's Baa2/P-2 ratings for downgrade

Moody's Ratings (Moody's) placed the ratings of Baxter International Inc. (Baxter) on review for downgrade. The ratings placed on review include the Baa2 senior unsecured ratings and Prime-2 commercial paper rating. Previously, the outlook was negative. The review is prompted by operating pressure...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch